A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver.

Trial Profile

A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Cancer; Liver metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center.
    • 23 Mar 2013 Planned number of patients changed from 60 to 80, as reported by M.D. Anderson Cancer Center.
    • 22 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top